CD274 and neoplasm: Building on previous findings, we explored rupatadine’s potential to enhance anti-tumor immunity in DLBCL by transplanting tumors from Eμ-myc lymphoma mice subcutaneously into healthy mice, and treating them with PD-L1 monoclonal antibodies, rupatadine, or both (Fig. 7F).